Evotec SE and Biocon Limited today announced that Biocon Biologics, a wholly owned subsidiary of Biocon Ltd, and Just – Evotec Biologics, wholly owned by Evotec, have entered into a strategic licensing agreement for an early-stage, pre-clinical biosimilar asset. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/just—evotec-biologics–biocon-biologics-sign-licensing-deal-for-a-biosimilar-asset-5856
Evotec and Celmatix enter into strategic collaboration
Evotec SE and Celmatix Inc., a precision medicine company with a proprietary multi-omics platform, today announced a partnership to develop pre-clinical programmes in prevalent but underserved conditions affecting women’s reproductive health, including polycystic ovary syndrome (“PCOS”), endometriosis, and infertility. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celmatix-enter-into-strategic-collaboration-5854
Evotec reaches milestone in integrated drug discovery and development partnership with Aeovian
Evotec SE today announced that the Company has reached a milestone in a drug discovery and development partnership with the biopharmaceutical company Aeovian Pharmaceuticals, Inc. (“Aeovian“). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reaches-milestone-in-integrated-drug-discovery-and-development-partnership-with-aeovian-5851
Evotec and Indivumed achieve milestone in joint strategic drug discovery collaboration
Evotec SE and Indivumed GmbH announced today that the first milestone has been successfully achieved in their joint collaboration to identify new therapeutic targets for the treatment of colorectal cancer. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-indivumed-achieve-milestone-in-joint-strategic-drug-discovery-collaboration-5849
Evotec and Takeda enter collaboration agreement to discover clinical candidates across multiple therapeutic areas
Evotec SE today announced a strategic, multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Under the collaboration, the parties aim to establish at least five drug discovery programmes with the goal of Evotec delivering clinical candidates for Takeda to pursue into clinical development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-takeda-enter-collaboration-agreement-to-discover-clinical-candidates-across-multiple-therapeutic-areas-5847
Evotec SE reports first half-year 2019 results and corporate updates
Evotec SE today reported financial results and corporate updates for the first half of 2019. Group revenues up 16% to € 207.1 m (H1 2018: € 178.9 m). Adjusted Group EBITDA up 51% to € 58.2 m (H1 2018: € 38.6 m). Unpartnered R&D expenses of € 18.7 m (H1 2018: € 10.0 m). Strong liquidity position of € 341.8 m (31 December 2018: € 149.4 m) following issue of € 250 m promissory note (Schuldschein) and final repayment of € 140 m acquisition bridge facility. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-reports-first-half-year-2019-results-and-corporate-updates-5843
Evotec SE to report first-half year 2019 results on 14 August 2019
Evotec SE will report its financial results for the first half of 2019 on Wednesday, 14 August 2019. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-report-first-half-year-2019-results-on-14-august-2019-5841
New IMI project “GNA NOW” kicks off its battle against antimicrobial resistance
Evotec SE and Lygature announced their cooperation in a new initiative for the development of novel antibacterial agents today: Gram-Negative Antibacterials NOW (“GNA NOW”). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/new-imi-project-gna-now-kicks-off-its-battle-against-antimicrobial-resistance-5839
Evotec SE: P2X3 antagonist demonstrates efficacy against refractory chronic cough in Phase II (POC)
Evotec SE today announced that the Company has been notified by its partner Bayer about the successful outcome of a combined Phase I/IIa study with the P2X3 antagonist BAY1817080, originating from the Evotec/Bayer multi-target alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-p2x3-antagonist-demonstrates-efficacy-against-refractory-chronic-cough-in-phase-ii-poc-5837
Evotec expands its iPSC discovery platform
Evotec SE today announced that the Company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec’s iPSC platform, one of the leading iPSC-based discovery platforms in the industry. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-its-ipsc-discovery-platform-5833